CommercialPrior AuthHigh impact
Botulinum Toxin (CPB 0113, reviewed 2026-07-14)
Aetna·Neurology, Pain Management, Dermatology +3 more·Medical Policy
Effective date
Jul 14, 2026
We identified it
Aug 12, 2026
Summary
Aetna has updated its Botulinum Toxin policy (CPB 0113) to restrict Myobloc (rimabotulinumtoxinB) coverage by requiring documentation of contraindication, intolerance, or ineffective response to lower-cost alternatives (Botox, Daxxify, Dysport, Xeomin) before approval. This is a cost-containment measure that will affect prior authorization requirements and claim denials if not properly documented.
Action Required
IMMEDIATELY: Billing team and providers must update prior authorization processes for all Aetna botulinum toxin requests, effective July 14, 2026. (1) For Myobloc (rimabotulinumtoxinB) requests for cervical dystonia: Require documentation that member has failed or is contraindicated/intolerant to ALL four alternatives (Botox, Daxxify, Dysport, Xeomin) before submitting for precertification. (2) For Myobloc requests for chronic sialorrhea: Require documentation of failure/contraindication/intolerance to Xeomin only. (3) For all other botulinum toxin products (Botox, Daxxify, Dysport, Xeomin): Continue standard prior authorization requirements but be prepared to deny Myobloc claims lacking proper step-therapy documentation. (4) Update EMR/EHR templates to include required documentation fields for Myobloc justification. (5) Providers must document on Statement of Medical Necessity (SMN) precertification forms why lower-cost alternatives are not suitable. Contact Aetna specialty pharmacy precertification at (866) 752-7021 or fax (888) 267-3277. CONSEQUENCE: Claims for Myobloc without documented contraindication/intolerance/ineffective response to required alternatives will be denied as not medically necessary.